Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

NCT05499013 is registered in ClinicalTrials.gov with Silence Therapeutics plc as lead sponsor.

NCT NCT05499013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05499013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera
Lead sponsor
Silence Therapeutics plc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 26, 2023
Completion date
March 31, 2030
Enrollment
69 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera